Market revenue in 2023 | USD 117.7 million |
Market revenue in 2030 | USD 350.9 million |
Growth rate | 16.9% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.67% in 2023. Horizon Databook has segmented the Germany crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for a substantial revenue share in Europe’s CRISPR and Cas gene market. It has several institutes and universities that are actively involved in the adoption of CRISPR techniques to serve their research purposes, thereby, boosting revenue generation in this country.
In March 2020, researchers from German universities, namely the Martin Luther University Halle-Wittenberg and the Science of Pathogens, developed a Cas9 variant that is designed to increase the specificity of CRISPR technology. Such studies are anticipated to optimize CRISPR-Cas9 technology in this region.
Merck KGaA is one of the prominent players in this region. Besides, strategic initiatives undertaken by other players are expected to drive the country’s market growth over the forecast period. In November 2017, CRISPR Therapeutics, along with Casebia Therapeutics, collaborated with the German biopharmaceutical company CureVac AG.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into Germany crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account